5′‐nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate‐risk cytogenetics
- 16 September 2022
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 109 (6) , 755-764
Abstract
Acute myeloid leukemia (AML) is a complex disease, and its treatment needs to be adjusted to the risk, which is conferred by cytogenetics and molecular markers. Cytarabine is the main drug to treat AML, and it has been suggested that the genotype of cytarabine metabolizing enzymes may have a prognostic relevance in AML. Here we report the association between the 5′‐nucleotidase, cytosolic II (NT5C2) rs10883841, cytidine deaminase (CDA) rs2072671 and rs532545 genotypes and the clinical outcome of 477 intermediate‐risk cytogenetic AML patients receiving cytarabine‐based chemotherapy. Patients younger than 50 years old with the NT5C2 rs10883841 AA genotype had lower overall survival (OS) (p: .003; HR 2.16, 95% CI 1.29–3.61) and lower disease‐free survival (DFS) (p: .002; HR 2.45, 95% CI 1.41–4.27), associated to a higher relapse incidence (p: .010; HR 2.23, 95% CI 1.21–4.12). Interestingly, subgroup analysis showed that the negative effect of the NT5C2 rs10883841 AA genotype was detected in all subgroups except in patients with nucleophosmin mutation without high ratio FLT‐3 internal tandem duplication. CDA polymorphisms were associated with the complete remission rate after induction chemotherapy, without influencing OS. Further studies are warranted to determine whether this pharmacogenomic approach may be helpful to individualize AML treatment.Keywords
This publication has 17 references indexed in Scilit:
- Decreased survival in normal karyotype AML with single‐nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′‐nucleotidaseAmerican Journal of Hematology, 2013
- Genetic Variants in Cytosolic 5′-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid LeukemiaThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survivalLeukemia, 2009
- Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemiaBritish Journal of Haematology, 2009
- Differential Allelic Expression in Leukoblast from Patients with Acute Myeloid Leukemia Suggests Genetic Regulation of CDA, DCK, NT5C2, NT5C3, and TP53Drug Metabolism and Disposition, 2008
- Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotypeBlood, 2005
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeNew England Journal of Medicine, 2005
- Deoxycytidine kinase and cN‐II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabineBritish Journal of Haematology, 2003
- Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapyLeukemia, 2002